Leland Gershell
Stock Analyst at Oppenheimer
(4.58)
# 238
Out of 5,055 analysts
144
Total ratings
52.55%
Success rate
30.02%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Maintains: Outperform | $23 → $24 | $11.35 | +111.45% | 4 | Nov 14, 2025 | |
| ENGN enGene Holdings | Reiterates: Outperform | $30 → $33 | $8.06 | +309.43% | 3 | Nov 12, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $8 → $18 | $7.26 | +147.93% | 4 | Oct 29, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $32 → $36 | $29.00 | +24.14% | 7 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $73 → $87 | $43.52 | +99.91% | 8 | Sep 30, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $80 | $18.38 | +335.26% | 1 | Sep 3, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $47.25 | +132.80% | 9 | Aug 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $60 → $61 | $66.90 | -8.82% | 3 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Outperform | $490 | $460.54 | +6.40% | 8 | Aug 4, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $20 | $9.48 | +110.97% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $100.69 | +9.25% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 → $22 | $5.69 | +286.64% | 5 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $215 → $224 | $216.56 | +3.44% | 12 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $23.70 | +30.80% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $1.88 | +431.91% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $929.61 | -23.84% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $1.80 | +455.56% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $54.46 | +79.95% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $41.35 | +25.76% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.54 | +1,868.50% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $24.30 | +118.11% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.50 | +242.86% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $3.20 | +156,150.00% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $5.57 | +348.83% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $3.14 | +536.13% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $22.56 | +28.55% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $16.88 | +107.41% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.57 | +1,642.16% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.78 | +2,473.67% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $2.32 | +460.34% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $3.66 | +3,178.69% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.61 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $24.59 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.19 | +4,101.68% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $16.04 | - | 5 | Mar 31, 2020 |
Trevi Therapeutics
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $11.35
Upside: +111.45%
enGene Holdings
Nov 12, 2025
Reiterates: Outperform
Price Target: $30 → $33
Current: $8.06
Upside: +309.43%
Xeris Biopharma Holdings
Oct 29, 2025
Maintains: Outperform
Price Target: $8 → $18
Current: $7.26
Upside: +147.93%
Viridian Therapeutics
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $29.00
Upside: +24.14%
Crinetics Pharmaceuticals
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $43.52
Upside: +99.91%
Tectonic Therapeutic
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $18.38
Upside: +335.26%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $47.25
Upside: +132.80%
BridgeBio Pharma
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $66.90
Upside: -8.82%
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $460.54
Upside: +6.40%
Lexeo Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $9.48
Upside: +110.97%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $100.69
Upside: +9.25%
Jun 23, 2025
Maintains: Outperform
Price Target: $43 → $22
Current: $5.69
Upside: +286.64%
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $216.56
Upside: +3.44%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $23.70
Upside: +30.80%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $1.88
Upside: +431.91%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $929.61
Upside: -23.84%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.80
Upside: +455.56%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $54.46
Upside: +79.95%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $41.35
Upside: +25.76%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.54
Upside: +1,868.50%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $24.30
Upside: +118.11%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.50
Upside: +242.86%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $3.20
Upside: +156,150.00%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $5.57
Upside: +348.83%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $3.14
Upside: +536.13%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $22.56
Upside: +28.55%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $16.88
Upside: +107.41%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.57
Upside: +1,642.16%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.78
Upside: +2,473.67%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $2.32
Upside: +460.34%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $3.66
Upside: +3,178.69%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $8.61
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $24.59
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.19
Upside: +4,101.68%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $16.04
Upside: -